应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
IBD Inspire Corporate Bond ETF
休市中 08-21 16:00:00 EDT
23.64
-0.02
-0.08%
盘后
23.64
+0.00
0.00%
19:30 EDT
最高
23.71
最低
23.60
成交量
8.75万
今开
23.67
昨收
23.66
日振幅
0.49%
总市值
4.94亿
流通市值
4.94亿
总股本
2,090万
成交额
206.84万
换手率
0.42%
流通股本
2,090万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Vivosim Labs, Inc.盘中异动 急速上涨5.41%
市场透视 · 02-26
Vivosim Labs, Inc.盘中异动 急速上涨5.41%
中国抗体-B(03681)：SM17用于治疗IBD的IND获NMPA批准
智通财经 · 02-24
中国抗体-B(03681)：SM17用于治疗IBD的IND获NMPA批准
Organovo Holdings, Inc.盘中异动 下午盘快速下跌6.37%报0.422美元
市场透视 · 2025-03-11
Organovo Holdings, Inc.盘中异动 下午盘快速下跌6.37%报0.422美元
Organovo Holdings, Inc.盘中异动 快速下挫6.10%
市场透视 · 2025-03-05
Organovo Holdings, Inc.盘中异动 快速下挫6.10%
艾伯维杀入减重赛道 寻找下一个“药王”？
新京报 · 2025-03-04
艾伯维杀入减重赛道 寻找下一个“药王”？
Organovo Holdings, Inc.股价重挫10.77% 市值跌109.04万美元
市场透视 · 2025-03-03
Organovo Holdings, Inc.股价重挫10.77% 市值跌109.04万美元
Organovo Holdings, Inc.盘中异动 早盘大幅跳水5.55%
市场透视 · 2025-02-28
Organovo Holdings, Inc.盘中异动 早盘大幅跳水5.55%
Organovo Holdings, Inc.盘中异动 早盘股价大跌8.09%
市场透视 · 2025-02-27
Organovo Holdings, Inc.盘中异动 早盘股价大跌8.09%
Organovo Holdings, Inc.股价拉升11.82% 市值涨292.98万美元
市场透视 · 2025-02-26
Organovo Holdings, Inc.股价拉升11.82% 市值涨292.98万美元
Organovo Holdings, Inc.股价上涨238.75% 市值涨5209.05万美元
市场透视 · 2025-02-25
Organovo Holdings, Inc.股价上涨238.75% 市值涨5209.05万美元
Organovo Holdings, Inc.盘中异动 股价大跌5.15%报0.350美元
市场透视 · 2025-02-25
Organovo Holdings, Inc.盘中异动 股价大跌5.15%报0.350美元
Organovo Holdings, Inc.盘中异动 股价大跌5.51%
市场透视 · 2025-02-20
Organovo Holdings, Inc.盘中异动 股价大跌5.51%
Organovo Holdings, Inc.盘中异动 股价大跌5.96%报0.363美元
市场透视 · 2025-02-18
Organovo Holdings, Inc.盘中异动 股价大跌5.96%报0.363美元
Organovo Holdings, Inc.盘中异动 股价大涨5.82%报0.400美元
市场透视 · 2025-02-15
Organovo Holdings, Inc.盘中异动 股价大涨5.82%报0.400美元
Organovo Holdings, Inc.盘中异动 早盘快速拉升5.02%
市场透视 · 2025-02-13
Organovo Holdings, Inc.盘中异动 早盘快速拉升5.02%
MNC年报扫描｜巨头“厮杀” 国产“逐鹿”：自免领域5大单品狂揽近530亿美元
21世纪经济报道 · 2025-02-07
MNC年报扫描｜巨头“厮杀” 国产“逐鹿”：自免领域5大单品狂揽近530亿美元
【礼来(LLY.US)IL-23p19单抗mirikizumab获批克罗恩病新适应症】1月15日，礼来(LLY.US)宣布，其IL-23p19单抗mirikizumab(Omvoh)已获FDA批准第2项适应症，用于治疗成人中度至重度活动性克罗恩病。Mirikizumab继2023年10月被批准为治疗中度至重度活动性成人溃疡性结肠炎(UC)的同类首创疗法之后，现在又被批准用于治疗两种类型的炎症性肠病(IBD)。
金融界 · 2025-01-16
【礼来(LLY.US)IL-23p19单抗mirikizumab获批克罗恩病新适应症】1月15日，礼来(LLY.US)宣布，其IL-23p19单抗mirikizumab(Omvoh)已获FDA批准第2项适应症，用于治疗成人中度至重度活动性克罗恩病。Mirikizumab继2023年10月被批准为治疗中度至重度活动性成人溃疡性结肠炎(UC)的同类首创疗法之后，现在又被批准用于治疗两种类型的炎症性肠病(IBD)。
MNC年度涨幅榜，意外的榜一
蓝鲸财经 · 2025-01-10
MNC年度涨幅榜，意外的榜一
医药行业周报：艾伯维将以2亿美元收购NIMBLE 布局自免领域
太平洋证券股份... · 2024-12-17
医药行业周报：艾伯维将以2亿美元收购NIMBLE 布局自免领域
加载更多
公司概况
公司名称：
Inspire Corporate Bond ETF
所属市场：
ARCA
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"IBD","market":"US","secType":"STK","nameCN":"Inspire Corporate Bond ETF","latestPrice":23.64,"timestamp":1787342400000,"preClose":23.66,"halted":0,"volume":87513,"hourTrading":{"tag":"盘后","latestPrice":23.64,"preClose":23.64,"latestTime":"19:30 EDT","volume":15,"amount":354.6,"timestamp":1787355005393,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0008453085376162119,"floatShares":20898591,"shares":20898591,"eps":0,"marketStatus":"休市中","change":-0.02,"latestTime":"08-21 16:00:00 EDT","open":23.67,"high":23.71,"low":23.5952,"amount":2068431.714204,"amplitude":0.004852,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":23.66,"sharesOutstanding":19800000,"nav":23.6,"aum":495681074.57,"dividendRate":0.042652,"bidAskSpread":0.001028,"postHourTrading":{"tag":"盘后","latestPrice":23.64,"preClose":23.64,"latestTime":"19:30 EDT","volume":15,"amount":354.6,"timestamp":1787355005393,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.9480173682917611},"requestUrl":"/m/hq/s/IBD","defaultTab":"news","newsList":[{"id":"2614049751","title":"Vivosim Labs, Inc.盘中异动 急速上涨5.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614049751","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2614049751?lang=zh_cn&edition=full","pubTime":"2026-02-26 04:11","pubTimestamp":1772050297,"startTime":"0","endTime":"0","summary":"北京时间2026年02月26日04时11分，Vivosim Labs, Inc.股票出现异动，股价快速上涨5.41%。Vivosim Labs, Inc.股票所在的生物技术行业中，整体跌幅为0.46%。Vivosim Labs, Inc.公司简介：VivoSim Labs Inc前身为Organovo Holdings Inc，是一家生物技术公司，专注于开发FXR314治疗炎症性肠病，包括溃疡性结肠炎，基于三维人体组织的临床前景证明以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226041137a4c85b45&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226041137a4c85b45&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IBD","VIVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613717630","title":"中国抗体-B(03681)：SM17用于治疗IBD的IND获NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2613717630","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2613717630?lang=zh_cn&edition=full","pubTime":"2026-02-24 22:01","pubTimestamp":1771941713,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国抗体-B 公布，于2026年2月24日，公司同类首创治疗产品SM17用于治疗炎症性肠病患者的新药临床试验申请已获中国国家药品监督管理局批准。公司已完成针对使用SM17皮下注射剂型的健康志愿者I期桥接实验的随访。该机制使SM17成为UC有前景的治疗候选药物，其中已证实IL-25发挥促炎作用。公司进一步认为，靶向2型炎性通路上游调控因子的治疗策略可支持SM17成为用于治疗AD及IBD的具差异化、安全性更佳且有效的治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406871.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","03681","BK1574","IND","IBD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518420501","title":"Organovo Holdings, Inc.盘中异动 下午盘快速下跌6.37%报0.422美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518420501","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518420501?lang=zh_cn&edition=full","pubTime":"2025-03-11 01:05","pubTimestamp":1741626341,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日01时05分，Organovo Holdings, Inc.股票出现异动，股价大幅下挫6.37%。截至发稿，该股报0.422美元/股，成交量27.3231万股，换手率1.57%，振幅8.70%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.64%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311010542abf34a26&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311010542abf34a26&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONVO","IBD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517908945","title":"Organovo Holdings, Inc.盘中异动 快速下挫6.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517908945","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517908945?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:43","pubTimestamp":1741185821,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时43分，Organovo Holdings, Inc.股票出现波动，股价急速下挫6.10%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.75%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305224341963adf65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305224341963adf65&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBD","BK4139","ONVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516260096","title":"艾伯维杀入减重赛道 寻找下一个“药王”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2516260096","media":"新京报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516260096?lang=zh_cn&edition=full","pubTime":"2025-03-04 18:00","pubTimestamp":1741082458,"startTime":"0","endTime":"0","summary":"艾伯维还是杀入了减重赛道。美国时间3月3日，艾伯维宣布与Gubra公司达成许可协议，共同开发用于治疗肥胖症的潜在同类最佳长效胰淀素类似物，交易总额最高可达22亿美元。当前减重赛道火热，2024年两款全球畅销减重药物更是合计卖出了457.42亿美元。自旗下修美乐因专利到期等因素销售开始下滑后，艾伯维业绩受到影响，近年来也在频频对外合作，提振业绩。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202503043336126264.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503043336126264.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516634704","title":"Organovo Holdings, Inc.股价重挫10.77% 市值跌109.04万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516634704","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516634704?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:30","pubTimestamp":1741012250,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时30分，Organovo Holdings, Inc.股票出现异动，股价大幅下跌10.77%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032230509637ab9c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032230509637ab9c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONVO","IBD","BK4139"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2514583373","title":"Organovo Holdings, Inc.盘中异动 早盘大幅跳水5.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514583373","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514583373?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:51","pubTimestamp":1740754266,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时51分，Organovo Holdings, Inc.股票出现异动，股价急速下挫5.55%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.22%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022822510696341eaf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022822510696341eaf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IBD","ONVO"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2514385603","title":"Organovo Holdings, Inc.盘中异动 早盘股价大跌8.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385603","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514385603?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:37","pubTimestamp":1740667027,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时37分，Organovo Holdings, Inc.股票出现波动，股价急速下挫8.09%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.85%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272237079632b21c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272237079632b21c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBD","BK4139","ONVO"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2514518578","title":"Organovo Holdings, Inc.股价拉升11.82% 市值涨292.98万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514518578","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514518578?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:32","pubTimestamp":1740580349,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时32分，Organovo Holdings, Inc.股票出现异动，股价快速拉升11.82%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.20%。其相关个股中，Enveric Biosciences, Inc.、Nutriband Inc C/Wts 、Channel Therapeutics Corporation涨幅较大，Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Cns Pharmaceuticals, Inc.较为活跃，换手率分别为2837.58%、119.45%、90.45%，振幅较大的相关个股有Enveric Biosciences, Inc.、Channel Therapeutics Corporation、Cns Pharmaceuticals, Inc.，振幅分别为35.59%、16.86%、14.35%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223230a254f6af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223230a254f6af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONVO","IBD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514090481","title":"Organovo Holdings, Inc.股价上涨238.75% 市值涨5209.05万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514090481","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514090481?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:31","pubTimestamp":1740493865,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时31分，Organovo Holdings, Inc.股票出现异动，股价急速上涨238.75%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.36%。其相关个股中，Organovo Holdings, Inc.、Moleculin Biotech, Inc.、Silexion Therapeutics Corp涨幅较大，Gt Biopharma, Inc.、Organovo Holdings, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为746.23%、508.78%、459.72%，振幅较大的相关个股有Organovo Holdings, Inc.、Igm Biosciences, Inc.、Bicara Therapeutics Inc.，振幅分别为8.13%、7.46%、5.62%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223105abdc7da6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223105abdc7da6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONVO","IBD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514670511","title":"Organovo Holdings, Inc.盘中异动 股价大跌5.15%报0.350美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514670511","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514670511?lang=zh_cn&edition=full","pubTime":"2025-02-25 04:35","pubTimestamp":1740429350,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日04时35分，Organovo Holdings, Inc.股票出现波动，股价快速跳水5.15%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体跌幅为0.14%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225043550962ee007&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225043550962ee007&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBD","BK4139","ONVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512480684","title":"Organovo Holdings, Inc.盘中异动 股价大跌5.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512480684","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512480684?lang=zh_cn&edition=full","pubTime":"2025-02-20 01:31","pubTimestamp":1739986261,"startTime":"0","endTime":"0","summary":"北京时间2025年02月20日01时31分，Organovo Holdings, Inc.股票出现波动，股价快速下跌5.51%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.37%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220013101988b4e5d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220013101988b4e5d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBD","ONVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512612521","title":"Organovo Holdings, Inc.盘中异动 股价大跌5.96%报0.363美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512612521","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512612521?lang=zh_cn&edition=full","pubTime":"2025-02-18 23:25","pubTimestamp":1739892328,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日23时25分，Organovo Holdings, Inc.股票出现波动，股价大幅下挫5.96%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.75%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218232528a24ab8fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218232528a24ab8fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBD","ONVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511137666","title":"Organovo Holdings, Inc.盘中异动 股价大涨5.82%报0.400美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511137666","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511137666?lang=zh_cn&edition=full","pubTime":"2025-02-15 02:04","pubTimestamp":1739556283,"startTime":"0","endTime":"0","summary":"北京时间2025年02月15日02时04分，Organovo Holdings, Inc.股票出现波动，股价大幅上涨5.82%。截至发稿，该股报0.400美元/股，成交量8.5386万股，换手率0.56%，振幅6.08%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体跌幅为0.50%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502150204439885bb0c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502150204439885bb0c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBD","BK4139","ONVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511243345","title":"Organovo Holdings, Inc.盘中异动 早盘快速拉升5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511243345","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511243345?lang=zh_cn&edition=full","pubTime":"2025-02-13 23:43","pubTimestamp":1739461383,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日23时43分，Organovo Holdings, Inc.股票出现波动，股价急速上涨5.02%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.50%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213234303abcdc059&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213234303abcdc059&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IBD","ONVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509791469","title":"MNC年报扫描｜巨头“厮杀” 国产“逐鹿”：自免领域5大单品狂揽近530亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509791469","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509791469?lang=zh_cn&edition=full","pubTime":"2025-02-07 16:39","pubTimestamp":1738917574,"startTime":"0","endTime":"0","summary":"随着跨国药企（MNC）陆续披露2024年业绩，21世纪经济报道记者初步统计发现，自免领域的营收排名中，赛诺菲的度普利尤单抗、艾伯维的利生奇珠单抗和阿达木单抗、强生的乌司奴单抗、罗氏的奥瑞利珠单抗位居前5，年内销售额合计529.31亿美元。在这5款产品中，度普利尤单抗作为全球首个获批上市的IL-4Rα靶向单抗，凭借不断拓宽的适应症，成为全球“自免新王”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202502073313516026.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502073313516026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CD","IBD","BK4116"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503916699","title":"【礼来(LLY.US)IL-23p19单抗mirikizumab获批克罗恩病新适应症】1月15日，礼来(LLY.US)宣布，其IL-23p19单抗mirikizumab(Omvoh)已获FDA批准第2项适应症，用于治疗成人中度至重度活动性克罗恩病。Mirikizumab继2023年10月被批准为治疗中度至重度活动性成人溃疡性结肠炎(UC)的同类首创疗法之后，现在又被批准用于治疗两种类型的炎症性肠病(IBD)。","url":"https://stock-news.laohu8.com/highlight/detail?id=2503916699","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503916699?lang=zh_cn&edition=full","pubTime":"2025-01-16 21:15","pubTimestamp":1737033339,"startTime":"0","endTime":"0","summary":"1月15日，礼来(LLY.US)宣布，其IL-23p19单抗mirikizumab(Omvoh)已获FDA批准第2项适应症，用于治疗成人中度至重度活动性克罗恩病。Mirikizumab继2023年10月被批准为治疗中度至重度活动性成人溃疡性结肠炎(UC)的同类首创疗法之后，现在又被批准用于治疗两种类型的炎症性肠病(IBD)。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/16211547534225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2237443465.HKD","LU0109391861.USD","LU2237443549.SGD","IE0004445239.USD","LU2264538146.SGD","LU1023059063.AUD","LU0256863811.USD","LU1057294990.SGD","LU0820561818.USD","SG9999001176.USD","SGXZ99366536.SGD","LU2023250504.SGD","BK4516","LU2063271972.USD","LU2112291526.USD","LU1988902786.USD","LU0320765059.SGD","IE0002141913.USD","LU2237443978.SGD","LU0094547139.USD","LU1061106388.HKD","LU1069344957.HKD","LU1712237335.SGD","SG9999001176.SGD","IBD","IE00BFTCPJ56.SGD","LU1974910355.USD","LU0122379950.USD","LU2491049909.HKD","SGXZ31699556.SGD","LU0058720904.USD","BK4585","LU0672654240.SGD","GB00BDT5M118.USD","LU2237438978.USD","LLY","LU0079474960.USD","LU1868837300.USD","LU0823416689.USD","LU2361045086.USD","LU0006306889.USD","LU1035775433.USD","LU0203202063.USD","IE00BK4W5L77.USD","LU0820561909.HKD","LU1983299246.USD","LU2461242641.AUD","LU2491050071.SGD","LU0106261372.USD","LU0385154629.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2502882548","title":"MNC年度涨幅榜，意外的榜一","url":"https://stock-news.laohu8.com/highlight/detail?id=2502882548","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2502882548?lang=zh_cn&edition=full","pubTime":"2025-01-10 14:58","pubTimestamp":1736492297,"startTime":"0","endTime":"0","summary":"都说铁打的大药企，流水的biotech。当超9成biotech跌跌不休之际，2022年全球领先的20家药企市值平均增长了5.4%。然而，到了2024年，大药企阵营也发生了分化。而股价涨幅最高的，则是仍处于转型爬坡阶段的梯瓦。整体来看，TOP20中，过去一年股价上涨与下跌企业各占一半。其中，梯瓦、礼来和吉利德是涨幅最高的三家大药企，拜耳、再生元和诺和诺德则是跌幅前三。真正的逆袭者，是以117%涨幅问鼎TOP20榜首的梯瓦。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/248993","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["CD","BK4116","IBD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2492588601","title":"医药行业周报：艾伯维将以2亿美元收购NIMBLE 布局自免领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2492588601","media":"太平洋证券股份...","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2492588601?lang=zh_cn&edition=full","pubTime":"2024-12-17 00:00","pubTimestamp":1734364800,"startTime":"0","endTime":"0","summary":"行业要闻：近日，艾伯维宣布，将以2 亿美元现金收购Nimble，并提供一定的中期资金支持和里程碑付款，从而获得其核心资产口服肽类IL-23 受体IL-23R 抑制剂，以及覆盖多种自身免疫疾病的创新口服肽候选药物管线。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217120201ab7e131c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217120201ab7e131c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0009355771.USD","LU0689472784.USD","LU2347655156.SGD","ABBV","LU1496350171.SGD","LU2023251221.USD","LU0965509010.AUD","BK4139","LU0310800379.SGD","LU0965508806.USD","LU1003077747.HKD","LU1989772923.USD","LU0417517546.SGD","LU0128525929.USD","LU0949170772.SGD","LU0256863902.USD","LU1732799900.SGD","IE00BDGV0183.EUR","IE00BFTCPJ56.SGD","LU1267930490.SGD","LU1244550221.USD","LU1732800096.USD","BK4550","SG9999003800.SGD","LU1291159041.SGD","LU1057294990.SGD","LU2237443895.HKD","LU1934455277.USD","IBD","LU0310799852.SGD","LU0708994859.HKD","BK4559","LU2237443622.USD","IE00B42XCP33.USD","LU0661504455.SGD","LU0861579265.USD","BK4585","IE0002141913.USD","LU0211328371.USD","SG9999011175.SGD","LU0795875169.SGD","BK4566","LU0985320562.USD","LU0965509283.SGD","LU0122379950.USD","IE00BGHQF631.EUR","LU0256863811.USD","LU0553294199.USD","LU0820561818.USD","BK4533"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.inspireetf.com/etf/inspire-corporate-bond-impact-etf/","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.0004},{"period":"3month","weight":-0.0028},{"period":"6month","weight":-0.0239},{"period":"1year","weight":-0.0179},{"period":"ytd","weight":-0.0231}],"compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":0.0245},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.1107},{"period":"1year","weight":0.2048},{"period":"ytd","weight":0.1229}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.001543},{"month":2,"riseRate":0.444444,"avgChangeRate":-0.005311},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.010014},{"month":4,"riseRate":0.444444,"avgChangeRate":0.000131},{"month":5,"riseRate":0.666667,"avgChangeRate":0.004486},{"month":6,"riseRate":0.555556,"avgChangeRate":0.001884},{"month":7,"riseRate":0.666667,"avgChangeRate":0.004234},{"month":8,"riseRate":0.6,"avgChangeRate":0.001795},{"month":9,"riseRate":0.222222,"avgChangeRate":-0.008441},{"month":10,"riseRate":0.222222,"avgChangeRate":-0.00662},{"month":11,"riseRate":0.555556,"avgChangeRate":0.009166},{"month":12,"riseRate":0.333333,"avgChangeRate":0.000853}],"exchange":"ARCA","name":"Inspire Corporate Bond ETF","nameEN":"Inspire Corporate Bond ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Inspire Corporate Bond ETF(IBD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Inspire Corporate Bond ETF(IBD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Inspire Corporate Bond ETF,IBD,Inspire Corporate Bond ETF股票,Inspire Corporate Bond ETF股票老虎,Inspire Corporate Bond ETF股票老虎国际,Inspire Corporate Bond ETF行情,Inspire Corporate Bond ETF股票行情,Inspire Corporate Bond ETF股价,Inspire Corporate Bond ETF股市,Inspire Corporate Bond ETF股票价格,Inspire Corporate Bond ETF股票交易,Inspire Corporate Bond ETF股票购买,Inspire Corporate Bond ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Inspire Corporate Bond ETF(IBD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Inspire Corporate Bond ETF(IBD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}